The RIT (Ras-like without CAAX) family of proteins, comprising RIT1 and RIT2, is a subgroup of the Ras superfamily of small GTPases. These proteins are unique within the Ras family due to the absence of a CAAX box at their C-terminus, which is typically involved in membrane attachment and post-translational modifications in other Ras proteins. RIT1 and RIT2 play significant roles in neuronal development, neuronal survival, and synaptic plasticity. They function as molecular switches, cycling between an active GTP-bound state and an inactive GDP-bound state, thereby regulating various downstream signaling pathways. RIT proteins are involved in the activation of key signaling cascades, including the MAPK/ERK pathway, which is crucial for cell growth, differentiation, and survival. Dysregulation of RIT signaling has been implicated in several disorders, including neurodevelopmental abnormalities and cancer, highlighting their importance in both normal cellular function and disease.
Targeting RIT (Ras-like without CAAX) proteins for disruption or inhibition using small molecules is a valuable approach for unraveling their mechanistic roles in cellular signaling. By inhibiting RIT proteins, researchers can directly observe the effects on downstream signaling pathways, such as the MAPK/ERK pathway, which is crucial for understanding their role in cell growth, differentiation, and survival. This approach enables the dissection of the RIT proteins' specific contributions to neuronal development and synaptic plasticity, areas where they are known to be particularly influential. Investigating the effects of RIT inhibition can also shed light on the mechanisms underlying various neurodevelopmental disorders and certain types of cancer, where RIT signaling is implicated.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Since RIT proteins activate the MAPK/ERK pathway, MEK inhibitors could indirectly affect their signaling. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Raf Inhibitors could indirectly affect RIT signaling pathways, particularly in cancer cells. | ||||||
Ambrisentan | 177036-94-1 | sc-207276 | 5 mg | $348.00 | ||
A farnesyltransferase inhibitor, which, while not specifically targeting RIT proteins, affects prenylation, a post-translational modification important in the function of many small GTPases. | ||||||
SCH772984 | 942183-80-4 | sc-473205 | 5 mg | $370.00 | 5 | |
As RIT proteins can activate ERK, inhibiting this pathway might indirectly affect RIT function. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
B-Raf inhibitors might have an indirect impact on RIT protein signaling in certain contexts. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $137.00 $512.00 | 7 | |
Cdc42/Rac1 GTPase inhibitors could potentially affect signaling pathways related to RIT proteins. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK Inhibitors could indirectly influence pathways associated with RIT proteins, especially in stress responses and apoptosis. | ||||||